About TherapeuticsMD, Inc.
https://www.therapeuticsmd.comTherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
CEO
Marlan D. Walker
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-05-09 | Reverse | 1:50 |
| 2011-10-31 | Reverse | 1:100 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
RUBRIC CAPITAL MANAGEMENT LP
Shares:1.19M
Value:$2.55M
CLEARLINE CAPITAL LP
Shares:635.22K
Value:$1.36M
VANGUARD GROUP INC
Shares:376.83K
Value:$806.41K
Summary
Showing Top 3 of 51
About TherapeuticsMD, Inc.
https://www.therapeuticsmd.comTherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $784K ▼ | $1.52M ▼ | $152K ▼ | 19.39% ▼ | $0.01 ▼ | $149K ▲ |
| Q2-2025 | $952K ▲ | $1.65M ▲ | $551K ▲ | 57.88% ▲ | $0.05 ▲ | $-223K ▲ |
| Q1-2025 | $393K ▼ | $1.26M ▲ | $-653K ▼ | -166.16% ▼ | $-0.06 ▼ | $-688K ▼ |
| Q4-2024 | $667K ▲ | $986K ▼ | $252K ▲ | 37.78% ▲ | $0.02 ▲ | $-212K ▲ |
| Q3-2024 | $547K | $1.41M | $-609K | -111.33% | $-0.05 | $-763K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.12M ▲ | $38.67M ▲ | $11.23M ▲ | $27.44M ▲ |
| Q2-2025 | $6.07M ▲ | $38.5M ▲ | $11.21M ▼ | $27.29M ▲ |
| Q1-2025 | $5.75M ▲ | $38.24M ▼ | $11.5M ▲ | $26.74M ▼ |
| Q4-2024 | $5.06M ▲ | $38.82M ▼ | $11.45M ▼ | $27.37M ▲ |
| Q3-2024 | $5.05M | $39.55M | $12.46M | $27.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $50K ▼ | $1.05M ▲ | $0 | $0 | $1.05M ▲ | $1.05M ▲ |
| Q2-2025 | $545K ▲ | $324K ▼ | $0 | $0 | $324K ▼ | $324K ▼ |
| Q1-2025 | $-636K ▼ | $686K ▲ | $0 | $0 | $686K ▲ | $686K ▲ |
| Q4-2024 | $252K ▲ | $12K ▲ | $0 | $0 | $12K ▲ | $12K ▲ |
| Q3-2024 | $-567K | $-185K | $0 | $0 | $-185K | $-185K |
Revenue by Products
| Product | Q1-2023 | Q1-2024 | Q2-2024 | Q3-2024 |
|---|---|---|---|---|
 License and Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Marlan D. Walker
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-05-09 | Reverse | 1:50 |
| 2011-10-31 | Reverse | 1:100 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
RUBRIC CAPITAL MANAGEMENT LP
Shares:1.19M
Value:$2.55M
CLEARLINE CAPITAL LP
Shares:635.22K
Value:$1.36M
VANGUARD GROUP INC
Shares:376.83K
Value:$806.41K
Summary
Showing Top 3 of 51